TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06150157: A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ 88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

Sponsor: Janssen Research & Development, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,880,104

Rescue Site Savings

+$4,555,320

Unlock Full NCT06150157 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06150157 Rescue Dossier →